Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: neuropathic pain therapeutics - Sangamo Therapeutics

Drug Profile

Research programme: neuropathic pain therapeutics - Sangamo Therapeutics

Alternative Names: Nav-1.7

Latest Information Update: 18 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sangamo Therapeutics
  • Class Analgesics; Gene therapies; Zinc finger DNA binding proteins
  • Mechanism of Action NAV1.7 voltage gated sodium channel expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Neuropathic pain

Most Recent Events

  • 13 Mar 2024 Sangamo Therapeutics plans to submit IND application for neuropathic pain therapeutics in Neuropathic pain the fourth quarter of 2024
  • 13 Mar 2024 Pharmacodynamics data from a preclinical trial in Neuropathic pain released by Sangamo Therapeutics
  • 23 May 2023 Nav 1.7 is available for licensing as of 23 May 2023. https://www.sangamo.com/collaborations (Sangamo therapeutics website; May 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top